The measurement of specific biomarkers is of key importance in medical and translational science, e.g. for diagnostic purposes, for patient selection in clinical trials, and for exploring treatment effect of therapeutics and therapeutic candidates in clinical trials. For many central nervous system (CNS)-related disorders, such as Alzheimer’s disease, there are despite large efforts no therapeutics available today that prevents, halts or cures the disease. The aim of the current project is to develop a method for exploring the efficacy of new treatments, by on-line measurement of clinically important biomarkers in the CNS. With such technologies at hand, it would be possible to obtain much more informative and conclusive data on the dosage, duration, and therapeutic potential of different treatments, as compared to what can be achieved today. A sensor-based device that would allow molecular recognition and on-line detection of the analyte (peptide or protein) of interest in real time directly in the target compartment would give new possibilities for monitoring the biomarkers of disease states and therapeutic intervention. The Fiber Optic-mediated Biomarker detection (FOB) developed in the project is based on a combination of in vivo compatible fiber optics for data transfer and SPR imaging for detection of molecular interactions. The SPR probes are functionalized with capture probes for specific capture of biomarker proteins to develop a sensor technology that can be used to monitor biomarkers of different pathological conditions in the CNS. The activities of the project include: i) coupling of the SPR sensor surfaces to fiber optic probes, ii) conjugation of suitable capture probes to the sensor surface, and iii) in vitro and in vivo studies to optimize the performance of the functionalized sensor.
Principle investigator: Amelie Eriksson Karlström, KTH
Partner: Alzecure (Johan Sandin)